Last SFr.104.60 CHF
Change Today -0.90 / -0.85%
Volume 11.6K
SANN On Other Exchanges
SANN is not on other exchanges.
As of 7:09 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (SANN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - SFr.106.90
52 Week Low
04/16/14 - SFr.3.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

santhera pharmaceuticals-reg (SANN) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (SANN) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications in North America and the EU. The company offers Raxone/Catena for the treatment of Friedreich’s Ataxia. Its products under development include Raxone/Catena, which is in preparation for regulatory re-submission marketing authorization in Europe for Leber's Hereditary Optic Neuropathy, in a Phase III study for Duchenne Muscular Dystrophy, and in a Phase II study for Primary Progressive Multiple Sclerosis; omigapil that is in Phase I pharmacokinetics study in pediatric patients with Congenital Muscular Dystrophy; and Fipamezole, which has completed Phase IIb study for treatment of Dyskinesia in Parkinson's disease. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

11.8 Employees
Last Reported Date: 04/7/14
Founded in 2004

santhera pharmaceuticals-reg (SANN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.326.4K
Compensation as of Fiscal Year 2013.

santhera pharmaceuticals-reg (SANN) Key Developments

Santhera Pharmaceuticals Holding AG Presents at German Equity Forum 2014, Nov-25-2014 06:00 PM

Santhera Pharmaceuticals Holding AG Presents at German Equity Forum 2014, Nov-25-2014 06:00 PM. Venue: Frankfurt, Germany. Speakers: Roland Grimm, VP - Finance, Thomas Meier, Chief Executive Officer.

Santhera Pharmaceuticals Holding AG Presents at Credit Suisse Swiss Midcap Conference, Nov-20-2014

Santhera Pharmaceuticals Holding AG Presents at Credit Suisse Swiss Midcap Conference, Nov-20-2014 . Venue: Zurich, Switzerland. Speakers: Thomas Meier, Chief Executive Officer.

Santhera Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the First Six Months Ended June 30, 2014

Santhera Pharmaceuticals reported unaudited consolidated earnings results for the first six months ended June 30, 2014. For the period, the company reported net sales were CHF 0.8 million, mainly driven by the first sales of Raxone for LHON under the cATU in France as well as sales for DMD and LHON patients under named patient and special access programs. As a result, the company narrowed its operating loss to CHF 3.1 million against CHF 4.8 million a year ago. The company reported an improved net result negative of CHF 3.1 million against CHF 3.2 million, which included extraordinary financial income of CHF 1.5 million from the settlement of finance lease liabilities. Basic and diluted loss per share was CHF 0.70 against CHF 0.88 a year ago. Operating cash flow negative was CHF 2,572,000 against CHF 4,119,000 a year ago. Financial result negative was CHF 101,569,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANN:SW SFr.104.60 CHF -0.90

SANN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SANN.
View Industry Companies

Industry Analysis


Industry Average

Valuation SANN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 449.0x
Price/Book 68.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 500.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTHERA PHARMACEUTICALS-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at